Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Valinomycin: Difference between pages
Appearance
(Difference between pages)
Content deleted Content added
Saving copy of the {{chembox}} taken from revid 458778293 of page Valinomycin for the Chem/Drugbox validation project (updated: 'ChemSpiderID', 'StdInChI', 'StdInChIKey'). |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5) (Maxim Masiutin - 18183 |
||
Line 1: | Line 1: | ||
{{cs1 config|name-list-style=vanc}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|chembox}}) taken from revid [{{fullurl:Valinomycin|oldid=458778293}} 458778293] of page [[Valinomycin]] with values updated to verified values.}} |
|||
{{chembox |
{{chembox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 470628010 |
||
| ImageFile = Valinomycin.svg |
| ImageFile = Valinomycin.svg |
||
| ImageSize = |
| ImageSize = |
||
| ImageAlt = Skeletal formula of valinomycin |
|||
| IUPACName = |
|||
| ImageFile1 = Valinomycin 3D ball.png |
|||
| ImageAlt1 = Ball-and-stick model of the valinomycin molecule |
|||
| IUPACName = cyclo[N-oxa-D-alanyl-D-valyl-N-oxa-L-valyl-D-valyl-N-oxa-D-alanyl-D-valyl-N-oxa-L-valyl-L-valyl-N-oxa-L-alanyl-L-valyl-N-oxa-L-valyl-L-valyl] |
|||
| OtherNames = |
| OtherNames = |
||
| |
|Section1={{Chembox Identifiers |
||
| Abbreviations = |
| Abbreviations = |
||
⚫ | |||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = 21493802 |
||
⚫ | |||
| ChEMBL = 223643 |
| ChEMBL = 223643 |
||
⚫ | |||
| ChEMBL = 216815 |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
| CASNo_Ref = {{cascite|correct|CAS}} |
||
| CASNo = 2001-95-8 |
| CASNo = 2001-95-8 |
||
| |
| DrugBank = DB14057 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
⚫ | |||
| UNII = N561YS75MN |
|||
⚫ | |||
| UNNumber = 2811 2588 |
|||
⚫ | | |
||
| EINECS = 217-896-6 |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | | StdInChI = 1S/C54H90N6O18/c1-22(2)34- |
||
| SMILES_Comment = <ref name="chemidplus">{{Cite web | url=https://chem.nlm.nih.gov/chemidplus/rn/2001-95-8 | title=ChemIDplus - 2001-95-8 - FCFNRCROJUBPLU-DNDCDFAISA-N - Valinomycin - Similar structures search, synonyms, formulas, resource links, and other chemical information | url-status = dead | archive-url = https://web.archive.org/web/20151220095207/https://chem.nlm.nih.gov/chemidplus/rn/2001-95-8 | archive-date = 20 December 2015 | website = [[Hazardous Substances Data Bank|TOXNET]] | publisher = U.S. National Library of Medicine}}</ref> |
|||
⚫ | |||
⚫ | | InChI = 1S/C54H90N6O18/c1-22(2)34-49(67)73-31(19)43(61)55-38(26(9)10)53(71)77-41(29(15)16)47(65)59-36(24(5)6)51(69)75-33(21)45(63)57-39(27(11)12)54(72)78-42(30(17)18)48(66)60-35(23(3)4)50(68)74-32(20)44(62)56-37(25(7)8)52(70)76-40(28(13)14)46(64)58-34/h22-42H,1-21H3,(H,55,61)(H,56,62)(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t31-,32-,33+,34-,35+,36+,37-,38-,39+,40+,41+,42+/m1/s1 |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | | StdInChI = 1S/C54H90N6O18/c1-22(2)34-49(67)73-31(19)43(61)55-38(26(9)10)53(71)77-41(29(15)16)47(65)59-36(24(5)6)51(69)75-33(21)45(63)57-39(27(11)12)54(72)78-42(30(17)18)48(66)60-35(23(3)4)50(68)74-32(20)44(62)56-37(25(7)8)52(70)76-40(28(13)14)46(64)58-34/h22-42H,1-21H3,(H,55,61)(H,56,62)(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t31-,32-,33-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m0/s1 |
||
⚫ | |||
⚫ | |||
| RTECS = |
| RTECS = |
||
| MeSHName = |
| MeSHName = |
||
⚫ | |||
⚫ | |||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = |
| KEGG = |
||
}} |
|||
| ATCCode = }} |
|||
| |
|Section2={{Chembox Properties |
||
| Formula = C<sub>54</sub>H<sub>90</sub>N<sub>6</sub>O<sub>18</sub> |
| Formula = C<sub>54</sub>H<sub>90</sub>N<sub>6</sub>O<sub>18</sub> |
||
| MolarMass = 1111.32 |
| MolarMass = 1111.32 g/mol |
||
| Appearance = White solid |
| Appearance = White solid |
||
| Density = |
| Density = |
||
| MeltingPtC = 190 |
|||
| MeltingPt = 172°C –177 °C |
|||
| |
| MeltingPt_notes = |
||
| BoilingPt = |
| BoilingPt = |
||
| |
| BoilingPt_notes = |
||
| Solubility = |
| Solubility = |
||
| SolubleOther = Methanol, ethanol, ethyl acetate, petrol-ether, dichloromethane |
| SolubleOther = Methanol, ethanol, ethyl acetate, petrol-ether, dichloromethane |
||
Line 53: | Line 61: | ||
| Viscosity = |
| Viscosity = |
||
| Dipole = }} |
| Dipole = }} |
||
| |
|Section3={{Chembox Structure |
||
| CrystalStruct = |
| CrystalStruct = |
||
| Coordination = |
| Coordination = |
||
| MolShape = |
| MolShape = |
||
| Dipole = }} |
| Dipole = }} |
||
| |
|Section5={{Chembox Thermochemistry |
||
| DeltaHf = |
| DeltaHf = |
||
| DeltaHc = |
| DeltaHc = |
||
| Entropy = |
| Entropy = |
||
| HeatCapacity = }} |
| HeatCapacity = }} |
||
| |
|Section6={{Chembox Pharmacology |
||
| AdminRoutes = |
| AdminRoutes = |
||
| Bioavail = |
| Bioavail = |
||
Line 75: | Line 83: | ||
| Legal_AU = |
| Legal_AU = |
||
| Legal_CA = |
| Legal_CA = |
||
| |
| Pregnancy_category = |
||
| |
| Pregnancy_AU = |
||
| |
| Pregnancy_US = }} |
||
| |
|Section4={{Chembox Explosive |
||
| ShockSens = |
| ShockSens = |
||
| FrictionSens = |
| FrictionSens = |
||
| |
| DetonationV = |
||
| REFactor = }} |
| REFactor = }} |
||
| |
|Section7={{Chembox Hazards |
||
| |
| ExternalSDS = |
||
| EUClass = |
|||
| EUIndex = |
|||
| MainHazards = Neurotoxicant |
| MainHazards = Neurotoxicant |
||
| NFPA-H = |
| NFPA-H = |
||
| NFPA-F = |
| NFPA-F = |
||
| NFPA-R = |
| NFPA-R = |
||
| NFPA- |
| NFPA-S = |
||
| GHSPictograms = {{GHS06}} |
|||
| RPhrases = |
|||
| |
| GHSSignalWord = Danger |
||
| HPhrases = {{H-phrases|300|310}} |
|||
| RSPhrases = |
|||
| PPhrases = {{P-phrases|262|264|270|280|301+310|302+350|310|321|322|330|361|363|405|501}} |
|||
| FlashPt = |
| FlashPt = |
||
| LD50 = 4 mg/kg (oral, rat)<ref name="chemidplus" /> |
|||
| Autoignition = |
|||
| AutoignitionPt = |
|||
| ExploLimits = |
| ExploLimits = |
||
| PEL = }} |
| PEL = }} |
||
| |
|Section8={{Chembox Related |
||
| OtherAnions = |
| OtherAnions = |
||
| OtherCations = |
| OtherCations = |
||
| |
| OtherFunction = |
||
| |
| OtherFunction_label = |
||
| |
| OtherCompounds = |
||
}} |
|||
}} |
}} |
||
'''Valinomycin''' is a naturally occurring dodeca[[depsipeptide]] used in the transport of [[potassium]] and as an [[antibiotic]]. Valinomycin is obtained from the cells of several ''[[Streptomyces]]'' species, ''[[Streptomyces fulvissimus|S. fulvissimus]]'' being a notable one. |
|||
It is a member of the group of natural neutral [[ionophore]]s because it does not have a residual charge. It consists of [[enantiomer]]s D- and L-valine (Val), D-[[alpha-hydroxyisovaleric acid]], and L-[[lactic acid]]. Structures are alternately bound via [[amide]] and [[ester]] bridges. Valinomycin is highly selective for [[potassium]] ions over [[sodium]] ions within the [[cell membrane]].<ref>{{cite journal |author1=Lars, Rose |author2=Jenkins ATA | title=The effect of the ionophore valinomycin on biomimetic solid supported lipid DPPTE/EPC membranes | journal= Bioelectrochemistry| year=2007 | volume=70 | issue=2 | pages=387–393 | doi=10.1016/j.bioelechem.2006.05.009 | pmid=16875886}}</ref> It functions as a potassium-specific transporter and facilitates the movement of potassium ions through lipid membranes "down" the electrochemical potential gradient.<ref>{{cite journal | author=Cammann K | title=Ion-selective bulk membranes as models | journal=Top. Curr. Chem. | year=1985 | volume=128 | pages=219–258| doi=10.1007/3-540-15136-2_8 | series=Topics in Current Chemistry | isbn=978-3-540-15136-4 }}</ref> The [[Equilibrium constant|stability constant]] K for the potassium-valinomycin complex is nearly 100,000 times larger than that of the sodium-valinomycin complex.<ref>{{cite journal|vauthors=Rose MC, Henkens RW |title=Stability of sodium and potassium complexes of valinomycin|journal=[[Biochimica et Biophysica Acta (BBA) - General Subjects]]|year=1974|volume=372|issue=2|pages=426–435|doi=10.1016/0304-4165(74)90204-9}}</ref> |
|||
This difference is important for maintaining the selectivity of valinomycin for the transport of potassium ions (and not sodium ions) in biological systems. |
|||
It is classified as an [[List of extremely hazardous substances|extremely hazardous substance]] in the United States as defined in Section 302 of the U.S. [[Emergency Planning and Community Right-to-Know Act]] (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.<ref name="gov-right-know">{{Cite web | publisher = [[United States Government Publishing Office|Government Printing Office]] | title = 40 C.F.R.: Appendix A to Part 355—The List of Extremely Hazardous Substances and Their Threshold Planning Quantities | url = http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf | edition = July 1, 2008 | access-date = October 29, 2011 | archive-date = February 25, 2012 | archive-url = https://web.archive.org/web/20120225051612/http://edocket.access.gpo.gov/cfr_2008/julqtr/pdf/40cfr355AppA.pdf | url-status = live }}</ref> |
|||
==Structure== |
|||
Valinomycin is a dodecadepsipeptide, that is, it is made of twelve alternating [[amino acid]]s and [[ester]]s to form a macrocyclic molecule. The twelve [[carbonyl]] groups are essential for the binding of metal ions, and also for [[solvation]] in [[solvent|polar solvents]]. The [[isopropyl]] and [[methyl]] groups are responsible for solvation in [[solvent|nonpolar solvent]]s. |
|||
<ref>{{cite journal |vauthors=Thompson M, Krull UJ|title=The electroanalytical response of the bilayer lipid membrane to valinomycin: membrane cholesterol content | journal=[[Anal. Chim. Acta]] | year=1982 | volume=141 | pages=33–47 | doi=10.1016/S0003-2670(01)95308-5|bibcode=1982AcAC..141...33T }}</ref> Along with its shape and size this molecular duality is the main reason for its binding properties. K ions must give up their water of hydration to pass through the pore. K<sup>+</sup> ions are octahedrally coordinated in a square bipyramidal geometry by 6 carbonyl bonds from Val. In this space of 1.33 Angstrom, Na<sup>+</sup> with its 0.95 Angstrom radius, is significantly smaller than the channel, meaning that Na<sup>+</sup> cannot form ionic bonds with the amino acids of the pore at equivalent energy as those it gives up with the water molecules. This leads to a 10,000x selectivity for K<sup>+</sup> ions over Na<sup>+</sup>. For polar solvents, valinomycin will mainly expose the carbonyls to the solvent and in nonpolar solvents the isopropyl groups are located predominantly on the exterior of the molecule. This conformation changes when valinomycin is bound to a potassium ion. The molecule is "locked" into a conformation with the isopropyl groups on the exterior [Citation Needed]. It is not actually locked into configuration because the size of the molecule makes it highly flexible, but the potassium ion gives some degree of coordination to the macromolecule. |
|||
== Applications == |
|||
Valinomycin was recently reported to be the most potent agent against severe acute respiratory-syndrome coronavirus (SARS-CoV) in infected [[Vero E6 cells]].<ref>{{Cite journal|last1=Zhang|first1=Dong|last2=Ma|first2=Zhi|last3=Chen|first3=Hanchi|last4=Lu|first4=Yuele|last5=Chen|first5=Xiaolong|date=October 2020|title=Valinomycin as a potential antiviral agent against coronaviruses: A review|journal=Biomedical Journal|volume=43|issue=5|pages=414–423|doi=10.1016/j.bj.2020.08.006|pmid=33012699|pmc=7417921|issn=2319-4170|doi-access=free}}</ref> |
|||
Valinomycin acts as a nonmetallic isoforming agent in [[potassium selective electrode]]s.<ref>{{cite journal |vauthors=Safiulina D, Veksler V, Zharkovsky A, Kaasik A | title=Loss of mitochondrial membrane potential is associated with increase in mitochondrial volume: physiological role in neurones | journal= [[J. Cell. Physiol.]] | year=2006 | volume=206 | issue=2 | pages=347–353 | doi=10.1002/jcp.20476 | pmid= 16110491| s2cid=34918061 }}</ref><ref>{{Cite web |url=http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Instructions/k_potassium.Par.0001.File.tmp/k_potassium.pdf |title=Potassium ionophore Bulletin |access-date=2009-05-19 |archive-date=2012-03-15 |archive-url=https://web.archive.org/web/20120315145943/http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Instructions/k_potassium.Par.0001.File.tmp/k_potassium.pdf |url-status=live }}</ref> |
|||
This ionophore is used to study [[Vesicle (biology and chemistry)|membrane vesicles]], where it may be selectively applied by experimental design to reduce or eliminate the electrochemical gradient across a membrane.{{citation needed|reason=Previous ref was not a valid URL|date=August 2019}} |
|||
== References == |
|||
{{Reflist}} |
|||
== External links == |
|||
* [http://www.state.nj.us/health/eoh/rtkweb/2850.pdf Chemical Safety Regulations] from [[New Jersey Department of Health]]. |
|||
* [http://www.scorecard.org/chemical-profiles/summary.tcl?edf_substance_id=2001-95-8 Health information on Scorecard] {{Webarchive|url=https://web.archive.org/web/20050518201502/http://www.scorecard.org/chemical-profiles/summary.tcl?edf_substance_id=2001-95-8 |date=2005-05-18 }}. |
|||
* [http://www.fermentek.com/product/valinomycin Valinomycin] from [[Fermentek]]. |
|||
* {{PPDB|2586}} |
|||
{{Nonribosomally synthesized porters}} |
|||
{{GABA metabolism and transport modulators}} |
|||
{{Glutamate metabolism and transport modulators}} |
|||
[[Category:Cyclic peptides]] |
|||
[[Category:Ionophores]] |
|||
[[Category:Depsipeptides]] |
|||
[[Category:Mitochondrial toxins]] |